NASDAQ: STSSSharps Technology Inc Stock
$0.34+0.01 (+3.03%)
Updated Feb 10, 2025
STSS Price
$0.34
Fair Value Price
$0.23
Market Cap
$616.64k
52 Week Low
$0.30
52 Week High
$18.15
P/E
-0.04x
P/B
0.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.73
Operating Cash Flow
-$8M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STSS Overview
Sharps Technology Incorporated is a medical device company that manufactures and sells safety syringe products in the U.S. Its 'Sharps Provensa' offering is a smart safety syringe designed to eliminate potentially infectious accidental needlestick injuries Sharps Technology was incorporated in 2017 and is headquartered in Melville, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STSS's potential to beat the market
- STSS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
A
STSS
RankedUnranked of 49
RankedUnranked of 49
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.12 | A | |
| $33.25 | A | |
| $4.65 | A |
Be the first to know about important STSS news, forecast changes, insider trades & much more!
STSS News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STSS ($0.34) is overvalued by 48.37% relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
STSS ($0.34) is not significantly undervalued (48.37%) relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
STSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more STSS due diligence checks available for Premium users.
Valuation
STSS fair value
Fair Value of STSS stock based on Discounted Cash Flow (DCF)
Price
$0.34
Fair Value
$0.23
Overvalued by
47.07%
STSS ($0.34) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
STSS ($0.34) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
STSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STSS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
40.12x
Market
31x
STSS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.09x
Industry
4.11x
STSS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STSS's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.7M
Profit Margin
0%
STSS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.3M
Liabilities
$4.7M
Debt to equity
0.73
STSS's short-term assets ($4.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STSS's short-term assets ($4.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$50.3k
Financing
$2.7M
STSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STSS vs Medical Stocks
Sharps Technology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.